This angiogenic phenomenon extends to other miRNAs derived from hepatocellular carcinoma (HCC), such as miR-210-3P, which targets SMAD4 and STAT6, as well as miR-100 derived from mesenchymal stem cells (MSCs), which induces angiogenesis in breast cancer by targeting the mTOR/HIF-1α/VEGF signaling axis [117, 118]. This evidence concerns the gene MTOR and hepatocellular carcinoma.